Protein A Resins Market

Global Protein A Resins Market Size (2024 to 2032)

The size of the global protein a resins market was valued at USD 532.9 million in 2023. The global market is anticipated to witness a CAGR of 8.2% from 2024 to 2032 and be valued at USD 1083.16 million by 2032 from USD 576.6 million in 2024.

The global market is showcasing the evident potential in the mentioned forecasting period. The growing demand for the best treatment of chronic diseases to get better results that are cost-effective and widely accepted. Protein A resins are commonly used in chromatography as well.

MARKET DRIVERS

The growing demand for monoclonal antibodies primarily drives the growth of the protein a resins market.

The demand for monoclonal antibodies is on the rise as they have been used in the treatment of various diseases, including cancer, autoimmune disorders and infectious diseases. Monoclonal antibodies offer targeted therapy, specificity and reduced side effects compared to traditional treatment options and growing applications of monoclonal antibodies are driving their demand. Protein A resins are used in the purification and isolation of mAbs from the cell culture supernatant or harvested cell culture fluid. The need for monoclonal antibodies is predicted to fuel in the coming years to address the growing patient population of chronic diseases, which is likely to boost the demand for protein a resins and drive the market growth.

The growing biopharmaceutical industry contributes to the growth of the protein a resins market.

The global biopharmaceuticals industry is expected to grow at a 9.2% CAGR between 2024 to 2032. The need for biopharmaceuticals is on the rise and the growing number of companies engaging in the R&D and production of biologics propels the market growth. Protein A resins are increasingly being used in the manufacturing process of biologics. The growing number of R&D activities in biopharmaceutical and biotechnology industries, the increasing number of advancements in chromatography techniques, the rising prevalence of chronic diseases such as cancer, autoimmune disorders and infectious diseases and an increasing number of technological advancements in protein a resins boost the market growth.

The growing market for biosimilars, supportive regulations and guidelines for the development and production of biopharmaceuticals by governments and regulatory bodies, growing investments in biotechnology and biopharmaceutical industries, rapid adoption of therapeutic antibodies and expansion of contract research organizations (CROs) and contract manufacturing organizations in the R&D and manufacturing of biopharmaceuticals further fuel the market growth. The growing healthcare expenditure in developing countries, rapid adoption of personalized medicine, increasing establishment and expansion of biomanufacturing facilities globally, strong emphasis on ensuring product quality and safety for biopharmaceuticals and increasing number of strategic collaborations and partnerships between the market participants to expand their product offerings, enhance technological capabilities, and enter new markets drive the protein a resins market growth.

MARKET RESTRAINTS

The expensive nature of protein a resins compared to other chromatography resins used in biopharmaceutical purification processes is one of the major factors hampering the market growth. The challenges associated with the production and supply chain of protein a resins due to manufacturing capacity constraints and complex production processes hinder the market growth. The availability of alternative purification technologies such as protein L resins, ion exchange chromatography, and mixed-mode chromatography is another significant roadblock to the market’s growth rate. Factors such as patent exclusivity, ethical concerns, regulatory requirements and guidelines for biopharmaceutical manufacturing, recycling and disposable challenges and technological advancements in downstream processing further inhibit the market’s growth rate.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Protein A Resins Market Analysis By Product Type

The recombinant protein A resins segment had the leading share of the global market in 2023 and is anticipated to account for the major share of the global market during the forecast period. The higher degree of purity and performance of recombinant compared to the natural protein A resins is one of the major factors driving the segmental growth. The growing number of therapeutic proteins and monoclonal antibodies being developed and ongoing advancements in recombinant protein production technologies, such as genetic engineering and cell culture techniques further propel the segmental growth. A favorable regulatory environment for recombinant protein A resins contributes to segmental growth.

Global Protein A Resins Market Analysis By Application

The immunoprecipitation segment is expected to register the fastest CAGR during the forecast period. The growing usage of immunoprecipitation in research activities by research laboratories to study protein-protein interactions, protein modifications, and protein localization, rising emphasis on biomedical research and drug discovery and an increasing number of advancements in proteomics and genomics and rising use of immunoprecipitation in biomedical and clinical applications, such as biomarker discovery, disease diagnostics and therapeutic target identification promote the segmental growth.

Global Protein A Resins Market Analysis By Matrix Type

The glass or silica-based matrix segment is expected to hold the leading share of the global market during the forecast period. Glass or silica-based Protein A resins is an established technology and has been used in the biopharmaceutical industry for many years. The continuous demand for glass or silica-based matrix technologies majorly drives segmental growth. The growing production activities of biopharmaceuticals further contribute to segmental growth.

Global Protein A Resins Market Analysis By End-User

The biopharmaceutical manufacturers segment is anticipated to lead the market during the forecast period. Biopharmaceutical companies extensively use protein A resins to purify monoclonal antibodies with great alarm. Therefore, the biopharmaceutical industry's development of therapeutic monoclonal antibodies is expected to rise to meet its growing demand. As monoclonal antibodies' production increases, the need for protein A resins for large-need purification will increase. In addition, the ever-increasing trend of outsourcing large-scale production to contract research organizations would also increase the clinical research laboratories' end-user segment in the market.

REGIONAL ANALYSIS

The North American region was the largest regional segment in the global market and accounted for approximately 37% in 2023. The domination of the North American regional market in the global market is anticipated to continue throughout the forecast period owing to the increasing investments in the development of monoclonal antibodies, followed by Europe. Factors such as the robust and well-established biopharmaceutical industry, the presence of numerous pharmaceutical companies and research institutions, technological advancements, and strong R&D capabilities majorly propel the growth of the North American market A stringent regulatory framework such as U.S. Food and Drug Administration (FDA) regulations to ensure the safety and quality of biopharmaceutical products further boost the growth rate of the North American market. The U.S. held the major share of the North American market in 2022 and is expected to continue throughout the forecast period.

The European market a notable share of the global market in 2023 and is expected to grow at a healthy CAGR during the forecast period. The significant presence of the biopharmaceutical industry in Europe with several leading companies and research institutions is one of the key factors driving the European market growth. The well-defined regulatory framework for biopharmaceutical products in Europe, rapid adoption of biosimilars, the presence of numerous CMOs that provide manufacturing services to biopharmaceutical companies and growing collaborative research initiatives among academia, industry, and government organizations contribute to the growth rate of the European market. Germany led the protein A resin market in Europe in 2022 and is expected to show a positive trend throughout the forecast period. The growing drug discovery and development activities and increasing demand for immunotherapy drugs to treat chronic diseases drive the German market growth. In addition, increased investments in protein research by the market participants favors the German market growth. Other European countries such as Sweden, Switzerland, Netherlands, and France are expected to have a healthy CAGR during the forecast period. The presence of the major market players in these countries has significantly impacted the European protein A resins market growth. In addition, the increasing rate of chronic diseases such as rheumatoid arthritis will generate significant market growth. For instance, in Sweden, the overall nationwide incidence of rheumatoid arthritis was around 42 per 100,000, with a high rate of incidences occurring in the age group of 70–79 years for both women and men. The UK Protein A resins market is expected to grow at over 7.4% CAGR during the forecast period. However, the increase in the adoption by various industries and the presence of the major market players in the country will influence the market's growth in the future. In addition, the region has a high demand for recombinant proteins, immunoglobulins, and protein antigen complexes, leading to an expansion of immunotherapy applications in the UK.

The Asia-Pacific is estimated to be the fastest-growing region worldwide during the forecast period. Factors such as the rapid growth in the biopharmaceutical sector, with an increasing number of companies involved in the development and production of biologics such as monoclonal antibodies, the presence of large population and rising healthcare expenditures further promote the APAC market growth. Countries such as China and India are emerging as major players in the biopharmaceutical industry, attracting investments and driving the demand for Protein A resins and fueling the growth rate of the APAC market. The growing number of advancements in healthcare infrastructure, regulatory reforms, and increasing research and development activities support the protein A resins market growth in the Asia-Pacific region.

Latin America is predicted to witness a healthy CAGR during the forecast period. The growing investments in the healthcare sector, increasing production of biologics including monoclonal antibodies, growing prevalence of chronic diseases and the rising adoption of advanced therapies majorly drive the Latin American market growth.

The MEA is anticipated to account for a moderate share of the global market during the forecast period.

KEY PLAYERS IN THE GLOBAL PROTEIN A RESINS MARKET

Companies leading the global protein A resins market profiled in the report are GE Healthcare, Repligen Corporation, Novasep, Tosoh Bioscience, GenScript, Thermo Fisher Scientific, EMD Millipore, and Expedeon Ltd. Major Players in the market enter into strategic agreements to develop raw materials required to manufacture Protein A resins.

DETAILED SEGMENTATION OF THE GLOBAL PROTEIN A RESINS MARKET INCLUDED IN THIS REPORT

This research report on the global protein a resins market has been segmented & sub-segmented based on the product type, application, end-user, matrix type, and region.

By Product Type

• Natural
• Recombinant

By Application

• Immunoprecipitation
• Antibody Purification

By Matrix Type

• Glass or Silica
• Agarose
• Organic Polymer

By End User

• Biopharmaceutical Manufacturers
• Clinical Research Laboratories
• Academic Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa